Exelixis, Inc. (NASDAQ:EXEL) Director Mary C. Beckerle Sells 12,210 Shares

Exelixis, Inc. (NASDAQ:EXEL) Director Mary C. Beckerle sold 12,210 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the completion of the transaction, the director now directly owns 30,406 shares of the company’s stock, valued at $1,060,561.28. This trade represents a 28.65 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Exelixis Stock Performance

Shares of EXEL stock opened at $35.09 on Friday. The firm’s 50-day moving average is $34.16 and its 200-day moving average is $31.14. The stock has a market cap of $9.82 billion, a price-to-earnings ratio of 19.82, a PEG ratio of 1.10 and a beta of 0.53. Exelixis, Inc. has a 52-week low of $20.14 and a 52-week high of $37.59.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Sell-side analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Barclays upped their target price on shares of Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Brookline Capital Management assumed coverage on shares of Exelixis in a research note on Monday, December 23rd. They issued a “buy” rating for the company. Citigroup upped their target price on shares of Exelixis from $38.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, February 12th. UBS Group upped their target price on shares of Exelixis from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Finally, Oppenheimer lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $41.00 to $33.00 in a research note on Friday, January 24th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Exelixis currently has an average rating of “Moderate Buy” and an average target price of $37.24.

Institutional Investors Weigh In On Exelixis

Institutional investors and hedge funds have recently modified their holdings of the company. Coppell Advisory Solutions LLC bought a new position in Exelixis in the 4th quarter valued at about $25,000. V Square Quantitative Management LLC bought a new position in Exelixis in the 3rd quarter valued at about $30,000. Colonial Trust Co SC raised its holdings in Exelixis by 616.9% in the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 765 shares during the period. USA Financial Formulas bought a new position in Exelixis in the 4th quarter valued at about $32,000. Finally, Principal Securities Inc. raised its holdings in Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 373 shares during the period. 85.27% of the stock is owned by institutional investors.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.